OkaiDx™ Breast Cancer Monitoring Blood Test

Booth No: M709

Characteristic

OkaiDx™ Breast Cancer Monitoring Blood Test is based on non-invasive cfDNA methylation analysis. With a simple blood draw, it detects breast cancer-related molecular signals and provides molecular-level adjunct monitoring information. After surgery, chemotherapy, radiation therapy, targeted therapy, or hormone therapy, breast cancer patients may still face the risk of minimal residual disease (MRD), recurrence, or disease progression. Clinical research data show that OkaiDx™ Breast Cancer Monitoring Blood Test achieves 95.1% accuracy, 89.4% sensitivity, and 96.5% specificity. It may help clinicians identify breast cancer-related molecular changes earlier and serve as an important adjunct reference for treatment response monitoring, recurrence risk management, and long-term disease monitoring. Compared with conventional CA15-3 and CEA tumor markers, OkaiDx™ analyzes cancer-related DNA methylation signals to provide molecular adjunct testing information with greater value for dynamic monitoring.
This test is suitable for adoption by healthcare institutions, health screening centers, and channel partners. It can be applied to post-treatment MRD monitoring, treatment response tracking, recurrence risk management, and long-term disease monitoring for breast cancer. The test is performed in a U.S. CLIA/CAP dual-certified clinical laboratory. Related breast cancer methylation testing technology has been patented in the United States, Europe, Japan, South Korea, China, Taiwan, Australia, Malaysia, and Singapore. EG BioMed can also help partners establish differentiated molecular testing services aligned with international quality standards.